Abstracts tagged "dermatomyositis"

Abstract Number: 1972 • ACR Convergence 2023
Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Christina Charles-Schoeman¹, Joachim Schessl², Rohit Aggarwal³ and and the ProDERM investigators⁴, ¹UCLA Medical Center, Santa Monica, CA, ²Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
Abstract Number: 1022 • ACR Convergence 2023
Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Joseph Fares¹, ross Summer¹ and Giorgos Loizidis², ¹The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA
Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
Abstract Number: 1249 • ACR Convergence 2023
Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward¹, Rebecca Sadun⁴, Jeffrey Dvergsten⁵, Ann Reed⁶, Mark Connelly⁷ and Laura Schanberg¹, ¹Duke University School of Medicine, Durham, NC, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of North Carolina School of Medicine, Chapel Hill, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Hillsborough, NC, ⁶Duke University School of Medicine, Chapel HIll, NC, ⁷Children's Mercy Kansas City / University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) patients are at high risk for cardiovascular disease (CVD). The American Heart Association cardiovascular health (CVH) construct is…
Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Denis Krutko¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵, Grant Cannon⁶ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…
Abstract Number: 1255 • ACR Convergence 2023
Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Sarah Molina¹, Dawn Gist², Marietta De Guzman³, Eyal Muscal⁴, Jamie Lai² and Maria Pereira³, ¹Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ²Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…
Abstract Number: 2461 • ACR Convergence 2023
Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies
Iago Pinal-Fernandez¹, Jose Cesar Milisenda², Katherine Pak¹, Sandra Muñoz-Braceras³, Maria Casal-Dominguez³, Jose Jiram Torres-Ruiz³, Stefania Dell´Orso⁴, Faiza Naz⁴, Gustavo Gutierrez-Cruz⁴, Yaiza Duque-Jaimez², Ana Matas-Garcia², Joan Padrosa⁵, Francesc J Garcia-Garcia², Mariona Guitart-Manpel², Gloria Garrabou², Ernesto Trallero-Araguas⁶, Brian Wallit⁷, Julie Paik⁸, Jemima Albayda⁸, Lisa Christopher-Stine⁸, Tom Lloyd⁹, Josep Maria Grau², Albert Selva-O’Callaghan⁶ and Andrew Mammen¹⁰, ¹National Institutes of Health, Bethesda, MD, ²Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, ³Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵CIBERER, Barcelona, Spain, Barcelona, Spain, ⁶Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁷National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, ⁸Johns Hopkins University, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰NIH, Bethesda, MD
Background/Purpose: Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (AS), and inclusion body myositis (IBM). Myositis-specific autoantibodies…
Abstract Number: 1155 • ACR Convergence 2023
Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis
Haruna Matsuo¹, Toshimasa Shimizu², Tomohiro Koga³, Nozomi Oki⁴, Mari Kamiya⁵, Natsuka Umezawa⁵, Shinsuke Yasuda⁶, Masataka Uetani⁷ and Atsushi Kawakami⁸, ¹Nagasaki University, Nagasaki City, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ⁴Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁶Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁷Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Nagasaki University, Nagasaki, Japan
Background/Purpose: Polymyositis/Dermatomyositis (PM/DM) is a chronic inflammatory disease characterized by muscle weakness, and cutaneous manifestations. Although PM/DM exhibits distinct disease phenotypes based on autoantibodies, assessing…
Abstract Number: 1587 • ACR Convergence 2023
Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity
Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
Abstract Number: 2462 • ACR Convergence 2023
Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications
Jorge Armando Gonzalez-Chapa¹, Jemima Albayda², Begum Horuluoglu³, Despina Michailidou¹, Marina Barguil Macedo¹, Lisa Christopher-Stine², Ingrid Lundberg⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Johns Hopkins University, Baltimore, MD, ³Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work…
Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Maximiliano Diaz Menindez¹, Megan Sullivan², Benjamin Wang³, Andy Abril³, Vikas Majithia², Ronald Butendieck³, Colleen T. Ball⁴ and Florentina Berianu², ¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Jacksonville, Jacksonville, FL
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
Abstract Number: 1588 • ACR Convergence 2023
Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Xiaoya Pei¹, Jia Shi², Yangzhong Zhou², Xiao Zhang², Xiaoman Wang¹, Mingwei Tang², Shuang Zhou², chanyuan wu², Jinmin Peng³, Mengtao Li⁴, xiaofeng Zeng², Jun Liu⁵, Houzao Chen¹ and Qian Wang², ¹State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…
Abstract Number: 2577 • ACR Convergence 2023
Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry
Astia Allenzara¹, Carolina Alvarez², Amanda Nelson³ and Galen Foulke⁴, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Idiopathic inflammatory myopathies confer an increased risk of morbidity from cardiovascular disease. Prior work has noted more than double risk of cardiovascular events for…
Abstract Number: 0023 • ACR Convergence 2023
Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
Avital Baniel¹, Mariko Ogawa-Momohara², Muhammad Bashir³, Rachita Pandya¹, Julianne Kleitsch¹, Felix Chin⁴, Ming-Lin Liu¹ and Victoria P. Werth⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…
Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Léa Debrut¹, Margherita Giannini², Céline Keime¹, Daniela Rovito¹, Béatrice Lannes³, Anne-Laure Charles⁴, Daniel Metzger¹, Bernard Geny⁵, Gilles Laverny¹ and Alain Meyer⁶, ¹Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France, ²Nouvel Hopital Civil, Strasbourg, Strasbourg, France, ³Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴UR3072, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France, ⁵Nouvel Hôpital Civil, Strasbourg, France, ⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…

« Previous Page
1
…
4
5
6
7
8
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].